Synbiotics in the Intensive Care Unit

Diya Mohammad, Lee E. Morrow

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.

Original languageEnglish
Title of host publicationProbiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion
PublisherElsevier Inc.
Pages585-592
Number of pages8
ISBN (Electronic)9780128023716
ISBN (Print)9780128021897
DOIs
StatePublished - Oct 8 2015

Fingerprint

Synbiotics
Intensive Care Units
Cross Infection
Prebiotics
Probiotics
Vulnerable Populations
Critical Care
Infection
Critical Illness
Sample Size
Comorbidity
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Mohammad, D., & Morrow, L. E. (2015). Synbiotics in the Intensive Care Unit. In Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion (pp. 585-592). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-802189-7.00043-5

Synbiotics in the Intensive Care Unit. / Mohammad, Diya; Morrow, Lee E.

Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. Elsevier Inc., 2015. p. 585-592.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mohammad, D & Morrow, LE 2015, Synbiotics in the Intensive Care Unit. in Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. Elsevier Inc., pp. 585-592. https://doi.org/10.1016/B978-0-12-802189-7.00043-5
Mohammad D, Morrow LE. Synbiotics in the Intensive Care Unit. In Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. Elsevier Inc. 2015. p. 585-592 https://doi.org/10.1016/B978-0-12-802189-7.00043-5
Mohammad, Diya ; Morrow, Lee E. / Synbiotics in the Intensive Care Unit. Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. Elsevier Inc., 2015. pp. 585-592
@inbook{1f138b54e46a4a9b8785e0e89de85eaa,
title = "Synbiotics in the Intensive Care Unit",
abstract = "Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.",
author = "Diya Mohammad and Morrow, {Lee E.}",
year = "2015",
month = "10",
day = "8",
doi = "10.1016/B978-0-12-802189-7.00043-5",
language = "English",
isbn = "9780128021897",
pages = "585--592",
booktitle = "Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Synbiotics in the Intensive Care Unit

AU - Mohammad, Diya

AU - Morrow, Lee E.

PY - 2015/10/8

Y1 - 2015/10/8

N2 - Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.

AB - Patients who require intensive care are a uniquely vulnerable population. Their concurrent comorbidities, altered nutrition, required medications, and impaired barrier function predisposes them to a host of complications including nosocomial infections. Unfortunately, such intensive care unit-acquired infections are increasingly caused by resistant pathogens, further complicating their optimal care. As such, nonantibiotic prophylaxis and/or treatment strategies are particularly appealing in this subset of patients. An increasing amount of literature, both basic science and clinical in nature. suggests that probiotic, prebiotic, and synbiotic therapies may be effective in reducing nosocomial infection rates and the adverse implications of these infections. Although existing synbiotic studies in critically ill populations often suffer from small sample sizes and methodologic limitations, our current collective knowledge suggests that synbiotic therapy is safe and viable across an array of disease states. This review summarizes our current knowledge in this area, including limitations to our current investigations.

UR - http://www.scopus.com/inward/record.url?scp=84967335341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967335341&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802189-7.00043-5

DO - 10.1016/B978-0-12-802189-7.00043-5

M3 - Chapter

SN - 9780128021897

SP - 585

EP - 592

BT - Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion

PB - Elsevier Inc.

ER -